Bruce Finkel, MD
Allergy & Immunology · Savannah, GANPI 1972562668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 294 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,340, 2.2 times the $622 reported in 2019.
Across 294 payments — averaging $21.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Octapharma USA, Inc.$892
- Novartis$567
- Sanofi$547
- Regeneron Healthcare Solutions, Inc.$515
- Grifols USA, LLC$488
- Pfizer$431
- plus $3K from 25 others
Across 28 payments — averaging $9675.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$222K
- AstraZeneca$32K
- Alk-abello, Inc$17K
- Merck$42
What the payments were for
- Food & beverage$6,26398%
- Education$1322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Octapharma USA, Inc. | 18 | $892 |
| Novartis | 31 | $567 |
| Sanofi | 20 | $547 |
| Regeneron Healthcare Solutions, Inc. | 21 | $515 |
| Grifols USA, LLC | 27 | $488 |
| Pfizer | 30 | $431 |
| AstraZeneca | 23 | $413 |
| CSL Behring | 16 | $379 |
| Genentech USA, Inc. | 17 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $285 |
| Kaleo, Inc. | 15 | $249 |
| Pharming Healthcare, Inc. | 12 | $221 |
| GSK | 13 | $217 |
| Optinose US, Inc. | 8 | $153 |
| Integra Lifesciences Corporation | 1 | $150 |
| Amgen(2 entities) | 5 | $105 |
| Hospira, Inc. | 3 | $59 |
| Alk-abello, Inc | 3 | $52 |
| Merck | 3 | $44 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Hikma Pharmaceuticals USA | 2 | $36 |
| Biocryst US Sales Co., LLC | 2 | $36 |
| GC Biopharma USA, Inc. | 1 | $28 |
| AbbVie | 1 | $21 |
| LEO Pharma Inc. | 1 | $20 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| USWM, LLC | 1 | $18 |
| Dermavant Sciences, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Acclarent Aera$150
- Inspira Air$150
- RELIEVA SPINPLUS NAV$150
- TruDi Probe$150
How this compares
$6,395 in reported general payments places this provider in the 55th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 11 | $35,374 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $30,768 |
| Epinephrine | 47 | $8,951 |
| Arnuity ElliptaFluticasone Furoate | 29 | $8,252 |
| Ipratropium Bromide | 175 | $7,239 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,235 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 30 | $7,167 |
| Azelastine Hcl | 200 | $6,791 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,769 |
| Zafirlukast | 40 | $4,635 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $3,957 |
| QnaslBeclomethasone Dipropionate | 13 | $3,841 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,692 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $3,587 |
| Fluticasone Propionate | 206 | $3,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $217 | $46,25686 claims |
| Hikma Pharmaceuticals USAEpinephrine | $36 | $8,95147 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl, Qvar Redihaler | $39 | $7,42826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Savannah
- Wasil KhanSavannah$7K
- Brad GoodmanSavannah$5K
- Monica KenneySavannah$5K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.